

Accepted Manuscript

Investigation of orexin-2 selective receptor antagonists: structural modifications resulting in dual orexin receptor antagonists

Jason W. Skudlarek, Christina N. DiMarco, Kerim Babaoglu, Anthony J. Roecker, Joseph G. Bruno, Mark A. Pausch, Julie A. O'Brien, Tamara D. Cabalu, Joanne Stevens, Joseph Brunner, Pamela L. Tannenbaum, W. Peter Wuelfing, Susan L. Garson, Steven V. Fox, Alan T. Savitz, Charles M. Harrell, Anthony L. Gotter, Christopher J. Winrow, John J. Renger, Scott D. Kuduk, Paul J. Coleman



PII: S0960-894X(17)30132-4
DOI: <http://dx.doi.org/10.1016/j.bmcl.2017.02.012>
Reference: BMCL 24684

To appear in: *Bioorganic & Medicinal Chemistry Letters*

Received Date: 13 January 2017
Revised Date: 3 February 2017
Accepted Date: 5 February 2017

Please cite this article as: Skudlarek, J.W., DiMarco, C.N., Babaoglu, K., Roecker, A.J., Bruno, J.G., Pausch, M.A., O'Brien, J.A., Cabalu, T.D., Stevens, J., Brunner, J., Tannenbaum, P.L., Peter Wuelfing, W., Garson, S.L., Fox, S.V., Savitz, A.T., Harrell, C.M., Gotter, A.L., Winrow, C.J., Renger, J.J., Kuduk, S.D., Coleman, P.J., Investigation of orexin-2 selective receptor antagonists: structural modifications resulting in dual orexin receptor antagonists, *Bioorganic & Medicinal Chemistry Letters* (2017), doi: <http://dx.doi.org/10.1016/j.bmcl.2017.02.012>

This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

**Investigation of orexin-2 selective receptor antagonists:
structural modifications resulting in dual orexin receptor antagonists**

Jason W. Skudlarek^{a,*}, Christina N. DiMarco^a, Kerim Babaoglu^b, Anthony J. Roecker^a, Joseph G. Bruno^c, Mark A. Pausch^c, Julie A. O'Brien^c, Tamara D. Cabalu^d, Joanne Stevens^e, Joseph Brunner^f, Pamela L. Tannenbaum^e, W. Peter Wuelfing^g, Susan L. Garson^f, Steven V. Fox^e, Alan T. Savitz^e, Charles M. Harrell^f, Anthony L. Gotter^f, Christopher J. Winrow^f, John J. Renger^f, Scott D. Kuduk[#], and Paul J. Coleman^a

^aDepartment of Medicinal Chemistry, MRL, Merck & Co., Inc., West Point, PA 19486, USA

^bDepartment of Chemical Capabilities & Screening, MRL, Merck & Co., Inc., West Point, PA 19486, USA

^cDepartment of In Vitro Pharmacology, MRL, Merck & Co., Inc., West Point, PA 19486, USA

^dDepartment of Drug Metabolism, MRL, Merck & Co., Inc., West Point, PA 19486, USA

^eDepartment of In Vivo Pharmacology, MRL, Merck & Co., Inc., West Point, PA 19486, USA

^fDepartment of Neuroscience, MRL, Merck & Co., Inc., West Point, PA 19486, USA

^gDiscovery Pharmaceutical Sciences, MRL, Merck & Co., Inc., West Point, PA 19486, USA

* Corresponding author. Tel.: + 1-215-652-2748 ; fax: + 1-215-652-3971.

E-mail address: jason_skudlarek@merck.com

[#]Current affiliation Novira Therapeutics, Inc., a part of Janssen Pharmaceuticals, Doylestown, PA 18902, USA

Abstract

In an ongoing effort to explore the use of orexin receptor antagonists for the treatment of insomnia, dual orexin receptor antagonists (DORAs) were structurally modified, resulting in compounds selective for the OX₂R subtype and culminating in the discovery of **23**, a highly potent, OX₂R-selective molecule that exhibited a promising *in vivo* profile. Further structural modification led to an unexpected restoration of OX₁R antagonism. Herein, these changes are discussed and a rationale for selectivity based on computational modeling is proposed.

Download English Version:

<https://daneshyari.com/en/article/5157142>

Download Persian Version:

<https://daneshyari.com/article/5157142>

[Daneshyari.com](https://daneshyari.com)